Showing results (191-200 of 403) with videos related to

Sort By:
Pageof 41
Pediatric Blood & Cancer|November 20, 2014
Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, Stephen T Keir, et al.
Expert Review of Anticancer Therapy|August 3, 2011
Management of adults with Wilms' tumor: recommendations based on international consensusHeidi Segers, Marry M van den Heuvel-Eibrink, Kathy Pritchard-Jones, et al.
Pediatric Blood & Cancer|February 22, 2011
Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing programPeter J Houghton, Richard Gorlick, E Anders Kolb, et al.
Cancer Research|March 18, 2010
Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma targetNaomi J Balamuth, Andrew Wood, Qun Wang, et al.
Pediatric Blood & Cancer|May 18, 2011
Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing programRichard B Lock, Hernan Carol, Christopher L Morton, et al.
Pediatric Blood & Cancer|January 11, 2013
Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing ProgramRichard B Lock, Hernan Carol, John M Maris, et al.
Cell Death and Differentiation|June 3, 2017
MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivationAlberto Delaidelli, Gian Luca Negri, Asad Jan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2022
Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for NeuroblastomaVandana Batra, Minu Samanta, Mehran Makvandi, et al.
The American Journal of Surgical Pathology|March 19, 2021
Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology GroupAsuka Kawano, Florette K Hazard, Bill Chiu, et al.
Pediatric Blood & Cancer|May 4, 2011
Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing programMin H Kang, C Patrick Reynolds, Peter J Houghton, et al.
Pageof 41